Bharat Biotech has joined hands with Australian institute

Hyderabad: City-based vaccine company Bharat Biotech International Ltd plans to design new approaches to tackle future pandemics and infectious diseases in collaboration with the University of Sydney Institute of Infectious Diseases (Sydney ID). An MoU has been signed between the two organizations to advance vaccine research initiatives, strengthen academic-industry partnerships, and enhance global efforts to combat infectious diseases.
Dr Krishna Ella, Executive Chairman, Bharat Biotech, said the agreement reflects their ethos to facilitate collaborative research, foster innovation and advance science vaccine technology. “Mutually, we look forward to new opportunities to strengthen our shared vision, leverage education and research capabilities to help build a healthier universe, and improve people’s lives by developing safe vaccine platforms.” Are excited. The most important thing is to nurture the talent of young scientists with a passion for innovation,” said Ella.

Professor Jamie Tricus, Deputy Director of Sydney ID with Bharat Biotech Sydney ID, said, “The reputational and societal impacts of the development of safe, affordable and effective new vaccines to eliminate human and animal diseases cannot be underestimated. ” Impact on global health.
Vaccines are the most effective and cost-effective way to protect billions of people worldwide, with vaccine development potentially transforming health by removing the burden of life-threatening infectious diseases from populations. India’s capabilities in vaccine manufacturing came to the fore during the COVID-19 pandemic, where companies like Bharat Biotech were able to provide vaccines meeting more than 60% of the world’s demand and delivered over 2.4 billion doses of COVID-19 vaccines Compensated. India continues to make significant R&D investments to develop a roadmap for the design and delivery of vaccine candidates for future pandemics.